JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takasawa, K.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takasawa, K.
Right arrow Articles by Sugiyama, Y.

Vol. 281, Issue 1, 369-375, 1997

In Vivo Evidence for Carrier-Mediated Efflux Transport of 3'-Azido-3'-Deoxythymidine and 2',3'-Dideoxyinosine Across the Blood-Brain Barrier via a Probenecid-Sensitive Transport System1

Katsuko Takasawa, Tetsuya Terasaki2, Hiroshi Suzuki and Yuichi Sugiyama

Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113, Japan

By analyzing the amount of ligand remaining in the brain after microinjection into the brain cortex, the apparent efflux rate constants (Keff) of 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (DDI) across the blood-brain barrier at low concentrations were determined to be 0.0317 ± 0.0068 min-1 and 0.0253 ± 0.0037 min-1, respectively. At higher concentrations, efflux exhibited saturation. The concentration of unlabeled DDI to inhibit 50% of the saturable efflux of [3H]DDI was found to be 11.3 ± 5.7 µM, assuming that DDI diffused into the same volume of brain as that of trypan blue after intracerebral administration. The efflux rate of [3H]AZT from the brain was significantly inhibited by DDI, probenecid, p-aminohippuric acid, benzylpenicillin and 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, but not by thymidine. Moreover, the efflux rate of [3H]DDI was significantly inhibited by AZT and probenecid, but not by deoxyinosine and inosine. After intracerebroventricular injection, the apparent efflux clearances of [3H]AZT and [3H]DDI from the cerebrospinal fluid were significantly inhibited by the coadministration of probenecid. However, intracerebroventricularly administered probenecid had no effect on the efflux of [3H]AZT and [3H]DDI from the brain after intracerebral microinjection, which suggested that the efflux transport system of the blood-cerebrospinal fluid barrier is not responsible for the elimination of AZT and DDI from the cerebral cortex. These results provide kinetic evidence that AZT and DDI are transported from brain into circulating blood across the blood-brain barrier via a probenecid-sensitive carrier-mediated efflux transport system.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
N. Giri, N. Shaik, G. Pan, T. Terasaki, C. Mukai, S. Kitagaki, N. Miyakoshi, and W. F. Elmquist
Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse
Drug Metab. Dispos., August 1, 2008; 36(8): 1476 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
G. Pan, N. Giri, and W. F. Elmquist
Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine
Drug Metab. Dispos., July 1, 2007; 35(7): 1165 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
W. M. Pardridge
BLOOD-BRAIN BARRIER DRUG TARGETING: THE FUTURE OF BRAIN DRUG DEVELOPMENT
Mol. Interv., March 1, 2003; 3(2): 90 - 105.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Alcorn and P. J. McNamara
Acyclovir, Ganciclovir, and Zidovudine Transfer into Rat Milk
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1831 - 1836.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. Yan and E. M. Taylor
Neotrofin Is Transported Out of Brain by a Saturable Mechanism: Possible Involvement of Multidrug Resistance and Monocarboxylic Acid Transporters
Drug Metab. Dispos., May 1, 2002; 30(5): 513 - 518.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
W. M. Pardridge
Targeting Neurotherapeutic Agents Through the Blood-Brain Barrier
Arch Neurol, January 1, 2002; 59(1): 35 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Lee, S. Dallas, M. Hong, and R. Bendayan
Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations
Pharmacol. Rev., December 1, 2001; 53(4): 569 - 596.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Y. Li, R. J. Boado, and W. M. Pardridge
Differential Kinetics of Transport of 2',3'-Dideoxyinosine and Adenosine via Concentrative Na+ Nucleoside Transporter CNT2 Cloned from Rat Blood-Brain Barrier
J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 735 - 740.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. Sugiyama, H. Kusuhara, Y. Shitara, T. Abe, P. J. Meier, T. Sekine, H. Endou, H. Suzuki, and Y. Sugiyama
Characterization of the Efflux Transport of 17beta -Estradiol-D-17beta -glucuronide from the Brain across the Blood-Brain Barrier
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 316 - 322.
[Abstract] [Full Text]

Home page
 Sex. Transm. Infect.Home page
S. Taylor and A. S Pereira
Antiretroviral drug concentrations in semen of HIV-1 infected men
Sex Transm Inf, February 1, 2001; 77(1): 4 - 11.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Hong, L. Schlichter, and R. Bendayan
A Novel Zidovudine Uptake System in Microglia
J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 141 - 149.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Kitazawa, T. Terasaki, H. Suzuki, A. Kakee, and Y. Sugiyama
Efflux of Taurocholic Acid Across the Blood-Brain Barrier: Interaction with Cyclic Peptides
J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 890 - 895.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Kusuhara, H. Suzuki, M. Naito, T. Tsuruo, and Y. Sugiyama
Characterization of Efflux Transport of Organic Anions in a Mouse Brain Capillary Endothelial Cell Line
J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1260 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Ooie, T. Terasaki, H. Suzuki, and Y. Sugiyama
Kinetic Evidence for Active Efflux Transport across the Blood-Brain Barrier of Quinolone Antibiotics
J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 293 - 304.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Takasawa, T. Terasaki, H. Suzuki, T. Ooie, and Y. Sugiyama
Distributed Model Analysis of 3'-Azido-3'-Deoxythymidine and 2',3'-Dideoxyinosine Distribution in Brain Tissue and Cerebrospinal Fluid
J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1509 - 1517.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
T. Ooie, T. Terasaki, H. Suzuki, and Y. Sugiyama
Quantitative Brain Microdialysis Study on the Mechanism of Quinolones Distribution in the Central Nervous System
Drug Metab. Dispos., July 1, 1997; 25(7): 784 - 789.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.